Eicosapentaenoic acid administration attenuates the pro-inflammatory properties of VLDL by decreasing its susceptibility to lipoprotein lipase in macrophages

Atherosclerosis

Volumn 219, Issue 2, 2011, Pages 566-572

  Jinno, Yasutaka ^a   Nakakuki, Masanori ^a   Kawano, Hiroyuki ^a   Notsu, Tatsuto ^a   Mizuguchi, Kiyoshi ^a   Imada, Kazunori ^a  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Eicosapentaenoic acid (EPA); Inflammatory; Macrophages; Very low density lipoprotein (VLDL)

Indexed keywords

APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; FATTY ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; LIPOPROTEIN LIPASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOLIPID; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME INHIBITION; EXTRACELLULAR SPACE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID COMPOSITION; LIPID HYDROLYSIS; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOLIPOPROTEIN C-II; APOLIPOPROTEIN C-III; BIOLOGICAL MARKERS; CELL LINE; CHEMOKINE CCL2; EICOSAPENTAENOIC ACID; ENZYME INHIBITORS; HUMANS; HYDROLYSIS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; LACTONES; LIPOPROTEIN LIPASE; LIPOPROTEINS, VLDL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PARTICLE SIZE; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 82955163073     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.046     Document Type: Article

References (25)

1. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
2. Rapp J.H., Lespine A., Hamilton R.L., et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994, 14:1767-1774.
3. Saraswathi V., Hasty A.H. The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages. J Lipid Res 2006, 47:1406-1415.
4. Stollenwerk M.M., Lindholm M.W., Pörn-Ares M.I., Larsson A., Nilsson J., Ares M.P. Very low-density lipoprotein induces interleukin-1β expression in macrophages. Biochem Biophys Res Commun 2005, 335:603-608.
5. Stollenwerk M.M., Schiopu A., Fredrikson G.N., Dichtl W., Nilsson J., Ares M.P. Very low density lipoprotein potentiates tumor necrosis factor-α expression in macrophages. Atherosclerosis 2005, 179:247-254.
6. Abe Y., Kawakami A., Osaka M., et al. Apolipoprotein CIII induces monocyte chemoattractant protein-1 and interleukin 6 expression via Toll-like receptor 2 pathway in mouse adipocytes. Arterioscler Thromb Vasc Biol 2010, 30:2242-2248.
7. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
8. Sato M., Katsuki Y., Fukuhara K., et al. Effects of highly purified ethyl all-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on rabbit platelets. Biol Pharm Bull 1993, 16:362-367.
9. Yano T., Kawano H., Yamashita M., Mizuguchi K., Mochizuki H., Iwamoto T. Effects of ethyl-all-cis-5,8,11,14,17-icosapentaenoate (EPA-E), pravastatin and their combination on serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits. Life Sci 1997, 61:2007-2015.
10. Itoh M., Suganami T., Satoh N., et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007, 27:1918-1925.
11. Sekiya M., Yahagi N., Matsuzaka T., et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003, 38:1529-1539.
12. Mizuguchi K., Yano T., Ishibashi M., Masada A., Mizota M., Saito Y. Ethyl all-cis-5,8,11,14,17-icosapentaenoate modifies the biochemical properties of rat very low-density lipoprotein. Eur J Pharmacol 1993, 235:221-227.
13. Calder P.C. Polyunsaturated fatty acids and inflammatory processes: new twists in an old tale. Biochimie 2009, 91:791-795.
14. Palmer A.M., Nova E., Anil E., et al. Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages. Atherosclerosis 2005, 180:233-244.
15. Merkel M., Loeffler B., Kluger M., et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005, 280:21553-21560.
16. Soltys P.A., Mazzone T., Wissler R.W., et al. Effects of feeding fish oil on the properties of lipoproteins isolated from rhesus monkeys consuming an atherogenic diet. Atherosclerosis 1989, 76:103-115.
17. Fisher R.M., Coppack S.W., Humphreys S.M., Gibbons G.F., Frayn K.N. Human triacylglycerol-rich lipoprotein subfractions as substrates for lipoprotein lipase. Clin Chim Acta 1995, 236:7-17.
18. Lambert D.A., Catapano A.L., Smith L.C., Sparrow J.T., Gotto A.M. Effect of the apolipoprotein C-II/C-III ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. Atherosclerosis 1996, 127:205-212.
19. Melin T., Qi C., Bengtsson-Olivecrona G., Akesson B., Nilsson A. Hydrolysis of chylomicron polyenoic fatty acid esters with lipoprotein lipase and hepatic lipase. Biochim Biophys Acta 1991, 1075:259-266.
20. Shimada M., Ishibashi S., Inaba T., et al. Suppression of diet-induced atherosclerosis in low density lipoprotein receptor knockout mice overexpressing lipoprotein lipase. Proc Natl Acad Sci USA 1996, 93:7242-7246.
21. Benlian P., De Gennes J.L., Foubert L., Zhang H., Gagné S.E., Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996, 335:848-854.
22. Babaev V.R., Patel M.B., Semenkovich C.F., Fazio S., Linton M.F. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem 2000, 275:26293-26299.
23. Van Eck M., Zimmermann R., Groot P.H., Zechner R., Van Berkel T.J. Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:E53-E62.
24. Wilson K., Fry G.L., Chappell D.A., Sigmund C.D., Medh J.D. Macrophage-specific expression of human lipoprotein lipase accelerates atherosclerosis in transgenic apolipoprotein E knockout mice but not in C57BL/6 mice. Arterioscler Thromb Vasc Biol 2001, 21:1809-1815.
25. Michaud S.E., Renier G. Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs. Diabetes 2001, 50:660-666.